The American Journal of Medicine
Volume 118, Issue 8 , Pages 890-898 , August 2005

Estimating the proportion of patients infected with HIV who will die of comorbid diseases

  • R. Scott Braithwaite, MD

      Affiliations

    • VAMC New Haven and Yale University School of Medicine, New Haven, Conn
    • Corresponding Author InformationCorrespondence should be addressed to R. Scott Braithwaite, MD, MSc, Assistant Professor of Medicine, Yale University School of Medicine, VA Connecticut Healthcare System, Mailstop 11-ACSLG, 950 Campbell Avenue, West Haven, CT 06516.
    • ,
  • Amy C. Justice, MD, PhD

      Affiliations

    • VAMC New Haven and Yale University School of Medicine, New Haven, Conn
    • ,
  • Chung-Chou H. Chang, PhD

      Affiliations

    • University of Pittsburgh Center for Research on Health Care, Department of Medicine, Pittsburgh, Penn
    • ,
  • Jennifer S. Fusco, BS

      Affiliations

    • GSK, Research Triangle Park, NC
    • ,
  • Stephen R. Raffanti, MD

      Affiliations

    • Comprehensive Care Center, Nashville, Tenn
    • ,
  • John B. Wong, MD

      Affiliations

    • Tufts-New England Medical Center, Boston, Mass.
    • ,
  • Mark S. Roberts, MD, MPP

      Affiliations

    • University of Pittsburgh Center for Research on Health Care, Department of Medicine, Pittsburgh, Penn

References 

  1. Landon BE , Wilson IB , Wenger NS , et al.   Specialty training and specialization among physicians who treat HIV/AIDS in the United States . J Gen Intern Med . 2002;17:12–22
  2. Hecht FM , Wilson IB , Wu AW , et al.  Society of General Internal Medicine AIDS Task Force   Optimizing care for persons with HIV infection . Ann Intern Med . 1999;131:136–143
  3. Keitz SA , Box TL , Homan RK , et al.   Primary care for patients infected with human immunodeficiency virus (a randomized controlled trial) . J Gen Intern Med . 2001;16:573–582
  4. Stone VE , Mansourati FF , Poses RM , Mayer KH . Relation of physician specialty and HIV/AIDS experience to choice of guideline-recommended antiretroviral therapy . J Gen Intern Med . 2001;16:360–368
  5. Kitahata MM , Van Rompaey SE , Shields AW . Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy . J Acquir Immune Defic Syndr . 2000;24:106–114
  6. Smith S , Robinson J , Hollyer J , et al.   Combining specialist and primary health care teams for HIV positive patients (retrospective and prospective studies) . BMJ . 1996;312:416–420
  7. Paauw DS , Wenrich MD , Curtis JR , et al.   Ability of primary care physicians to recognize physical findings associated with HIV infection . JAMA . 1995;274:1380–1382
  8. Curtis JR , Paauw DS , Wenrich MD , et al.   Physicians’ ability to provide initial primary care to an HIV-infected patient . Arch Intern Med . 1995;155:1613–1618
  9. Cohen MH , French AL , Benning L , et al.   Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy . Am J Med . 2002;113:91–98
  10. King JT , Justice AC , Roberts MS , et al.   Long-term HIV/AIDS survival estimation in the Highly-Active Antiretroviral Therapy era . Med Decis Making . 2003;23:9–20
  11. Schackman BR , Freedberg KA , Weinstein MC , et al.   Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults . Arch Intern Med . 2002;162:2478–2486
  12. Schackman BR , Goldie SJ , Weinstein MC , et al.   Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults . Am J Public Health . 2001;91:1456–1463
  13. Weinstein MC , Goldie SJ , Losina E , et al.   Use of genotypic resistance testing to guide HIV therapy (clinical impact and cost-effectiveness) . Ann Intern Med . 2001;134:440–450
  14. Walensky RP , Goldie SJ , Sax PE , et al.   Treatment for primary HIV infection (projecting outcomes of immediate, interrupted, or delayed therapy) . J Acquir Immune Defic Syndr . 2002;31:27–37
  15. Freedberg KA , Scharfstein JA , Seage GR , et al.   The cost-effectiveness of preventing AIDS-related opportunistic infections . JAMA . 1998;279:130–136
  16. Freedberg KA , Losina E , Weinstein MC , et al.   The cost effectiveness of combination antiretroviral therapy for HIV disease . N Engl J Med . 2001;344:824–831
  17. Phillips AN , Miller V , Sabin C , et al.   Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals . AIDS . 2001;15:2379–2384
  18. Paris D , Ledergerber B , Weber R , et al.   Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort . AIDS Res Hum Retroviruses . 1999;15:1631–1638
  19. Paterson DL , Swindells S , Mohr J , et al.   Adherence to protease inhibitor therapy and outcomes in patients with HIV infection . Ann Intern Med . 2000;133:21–30
  20. Lucas GM , Chaisson RE , Moore RD . Highly active antiretroviral therapy in a large urban clinic (risk factors for virologic failure and adverse drug reactions) . Ann Intern Med . 1999;131:81–87
  21. Howard AA , Arnsten JH , Lo Y , et al.   A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women . AIDS . 2002;16:2175–2182
  22. Le Moing V , Chene G , Carrieri MP , et al.   Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors . J Acquir Immune Defic Syndr . 2001;27:372–376
  23. Maher K , Klimas N , Fletcher MA , et al.   Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs Medical Center . J Acquir Immune Defic Syndr . 1999;22:358–363
  24. Haubrich RH , Little SJ , Currier JS , et al.  California Collaborative Treatment Group   The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response . AIDS . 1999;13:1099–1107
  25. Hogg RS , Yip B , Chan KJ , et al.   Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy . JAMA . 2001;286:2568–2577
  26. Mellors JW , Munoz A , Giorgi JV , et al.   Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection . Ann Intern Med . 1997;126:946–954
  27. Egger M , May M , Chene G , et al.   Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy (a collaborative analysis of prospective studies) . Lancet . 2002;360:119–129
  28. Hughes MD , Johnson VA , Hirsch MS , et al.  ACTG 241 Protocol Virology Substudy Team   Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response . Ann Intern Med . 1997;126:929–938
  29. Montaner JS , DeMasi R , Hill AM . The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count . AIDS . 1998;12:F23–F28
  30. Katzenstein DA , Hammer SM , Hughes MD , et al.  AIDS Clinical Trials Group Study 175 Virology Study Team   The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter . N Engl J Med . 1996;335:1091–1098
  31. Vlahov D , Graham N , Hoover D , et al.   Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users (plasma viral load and CD4+ cell count) . JAMA . 1998;279:35–40
  32. Anastos K , Kalish LA , Hessol N , et al.   The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1–infected women (results of the women’s interagency HIV study) . AIDS . 1999;13:1717–1726
  33. Miller V , Sabin CA , Phillips AN , et al.   The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load . AIDS . 2000;14:2129–2136
  34. Lundgren JD , Mocroft A , Gatell JM , et al.   A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy (results from the EuroSIDA study) . J Infect Dis . 2002;185:178–187
  35. Ledergerber B , Egger M , Opravil M , et al.   Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study . Lancet . 1999;353:863–868
  36. Grabar S , Le Moing V , Goujard C , et al.   Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy . Ann Intern Med . 2000;133:401–410
  37. Grabar S , Pradier C , Le Corfec E , et al.   Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor . AIDS . 2000;14:141–149
  38. Lepri AC , Katzenstein TL , Ullum H , et al.   The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection . AIDS . 1998;12:1639–1643
  39. US Dept of Health and Human Services, National Center for Health Statistics . Mortality, part B . Vital Statistics of the United States; Various Years Through 1991 . 1995;
  40. Becker SL , Raffanti SR , Hansen NI , et al.   Zidovudine and stavudine sequencing in HIV treatment planning (findings from the CHORUS HIV cohort) . J Acquir Immune Defic Syndr . 2001;26:72–81
  41. Welch HG , Albertsen PC , Nease RF , et al.   Estimating treatment benefits for the elderly (the effect of competing risks) . Ann Intern Med . 1996;124:577–584
  42. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AA_111003.html. Accessed November 20, 2003.

 This work was funded by National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health grants #1 K23 AA14483-01 and #UO1 AA13566-01, and National Library of Medicine grant #T15-LM07092-09.

PII: S0002-9343(05)00249-4

doi: 10.1016/j.amjmed.2004.12.034

The American Journal of Medicine
Volume 118, Issue 8 , Pages 890-898 , August 2005

Article Tools

* Image Usage & Resolution